^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    SC0245

    i
    Other names: SC0245, SC-0245, SC 0245
    Company:
    Shijiazhuang Sagacity, WuXi AppTec, Wuxi Biocity
    Drug class:
    ATR inhibitor
    Related drugs:
    over1year
    SC0245 and Irinotecan in Treating Patients With Relapsed Extensive-Stage Small Cell Lung Cancer (ES-SCLC) (clinicaltrials.gov)
    P1/2, N=67, Recruiting, Biocity Biopharmaceutics Co., Ltd. | Not yet recruiting --> Recruiting
    Enrollment open • Combination therapy
    |
    irinotecan • SC0245
    over4years
    [VIRTUAL] Preclinical evaluation of SC0245, a small molecule inhibitor of ATR kinase. (ASCO 2020)
    Moreover, in the SNU601 and LoVo CDX mouse models, SC0245 oral administration significantly inhibited tumor growth, with better efficacy than AZD6738. SC0245, a novel potent ATR kinase inhibitor, has marked antitumor efficacy in the ATM pathway or ARID1A deficient solid tumor animal models, and has outstanding PK properties. SC0245 represents a promising clinical candidate for treating solid cancers, such as gastric and colorectal cancers. Research Funding: Sagacity
    Preclinical
    |
    ARID1A (AT-rich interaction domain 1A) • CHEK1 (Checkpoint kinase 1)
    |
    ceralasertib (AZD6738) • SC0245